4//SEC Filing
Jewell Christopher M 4
Accession 0001453687-24-000128
CIK 0001453687other
Filed
Nov 17, 7:00 PM ET
Accepted
Nov 18, 7:23 PM ET
Size
16.4 KB
Accession
0001453687-24-000128
Insider Transaction Report
Form 4
Jewell Christopher M
Chief Scientific Officer
Transactions
- Sale
Common Stock
2024-11-14$17.02/sh−17,500$297,824→ 25,940 total - Exercise/Conversion
Common Stock
2024-11-15$3.23/sh+16,065$51,890→ 42,005 total - Sale
Common Stock
2024-11-15$17.06/sh−16,065$274,093→ 25,940 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-11-15−16,065→ 90,432 totalExercise: $3.23Exp: 2033-01-15→ Common Stock (16,065 underlying) - Sale
Common Stock
2024-11-14$16.34/sh−18,550$303,126→ 43,440 total - Exercise/Conversion
Common Stock
2024-11-14$3.23/sh+36,050$116,442→ 61,990 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-11-14−36,050→ 106,497 totalExercise: $3.23Exp: 2033-01-15→ Common Stock (36,050 underlying)
Footnotes (5)
- [F1]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.00 to $16.89. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.18. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.24. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The option is currently exercisable for 123,235 shares of Common Stock and becomes exercisable for an additional 2,969 shares of Common Stock each month until it is fully exercisable on June 16, 2025.
- [F5]On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.
Documents
Issuer
Cartesian Therapeutics, Inc.
CIK 0001453687
Entity typeother
Related Parties
1- filerCIK 0002000226
Filing Metadata
- Form type
- 4
- Filed
- Nov 17, 7:00 PM ET
- Accepted
- Nov 18, 7:23 PM ET
- Size
- 16.4 KB